Salute e Benessere

Bumrungrad International Hospital Achieves GHA Accreditation with "Excellence,"…

Artirat Charukitpipat, Ph.D., CEO of Bumrungrad International Hospital, stated, "Bumrungrad International Hospital has been a trusted leader in international medical tourism for over four decades. We care for patients from all over the world, as our patients come from over 190 countries. We are proud to have successfully earned our third GHA accreditation with "Excellence," which reflects our aim to advance our standards of healthcare quality and safety in delivering patient care…
PR Newswire
22/05/2024

AGC Biologics and BioConnection Partner to Offer new End-to-End…

AGC Biologics and BioConnection Partner to Offer new End-to-End BiopharmaceuticalDrugSubstanceandDrugProductDevelopment andManufacturingOffering Strategic partnership provides a seamless one-stop-shop for biopharmaceutical development andmanufacturingforlargepharma,mid-sizebiotech'sandstartupdevelopers.The AGC Biologics & BioConnection collaboration offers new option for companies evaluating thepotentialimpactofU.S....
Nasdaq GlobeNewswire
22/05/2024

Lycored Launches New Lumenato® Delivery Format, Offering Customers Expanded…

Lumenato is made of phytonutrients, like phytoene and phytofluene, and essential fatty acids that build a reservoir of goodness within the body; working from inside of the body out to support skin structure and protect collagen for improved elasticity, firmness, and more.1,2 This new liquid emulsion expands brands' opportunities to leverage the versatile benefits of Lumenato in new applications, including liquid and shot-style beverages, such as wellness shots. Lumenato is made of...
PR Newswire
22/05/2024

New German study shows Nevisense significantly improves dermatologists clinical…

"This is a very important study and results for SciBase as it quantifies the improvement in clinical decision-making possible with Nevisense even compared to dermsocopy. In Germany dermoscopy is standard of care for Dermatologists. The study showed that the addition of Nevisense further improved dermatologists' clinical performance. This is another publication that shows that Nevisense has a significant role in the diagnostic process to correctly identify malignant lesions in order to not…
PR Newswire
22/05/2024

Wolfpack Digital Clinches Webby Award for Responsible AI with "EqualityAI" at…

The award ceremony, held in New York City on May 13 2024, was a dazzling showcase of digital innovation and impact over the Internet. Wolfpack Digital's award was accepted by the company's co-CEOs, Georgina Lupu Florian and Adrian Florian. The award ceremony, held inNew York CityonMay 132024, was a dazzling showcase of digital innovation and impact over the Internet. Wolfpack Digital's award was accepted by the company's co-CEOs,Georgina Lupu FlorianandAdrian Florian. ...
PR Newswire
22/05/2024

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement…

Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseasesFelzartamab is an investigational anti-CD38 monoclonal antibody that, through its cell depletion approach, has demonstrated clinical proof of concept in rare immune-mediated indications, with plans to advance to Phase 3Proposed acquisition builds on Biogen capabilities in immunology with plans to combine Human Immunology...
Nasdaq GlobeNewswire
22/05/2024

Antion Biosciences announces development of safety-enhanced and off-the-shelf…

Aiming for a best-in-class solution to treat and cure B-cell driven autoimmune diseases Autoimmunity affects up to 10% of the global population, and the overall burden of care is believed to well-exceed US $120 billion per annum. Recent findings indicate that targeted CAR T-cell therapy is very effective in severe cases of autoimmune disease. According to pioneer, Prof. Dr. Georg Schett, one of Time Magazines Most Influential People in Health, “Not only are the patients in drug-free...
Nasdaq GlobeNewswire
22/05/2024

Global General Surgery Devices Market Size to Worth USD 30.33 Bn By 2031

Market Dynamics: Market Dynamics: The increasing prevalence of chronic diseases and the growing aging population are driving the demand for general surgery devices. Additionally, technological advancements in minimally invasive procedures are making surgeries safer and more efficient, further fueling market growth. The Full Study is Readily Available | Get Sample Pages of this Report:https://www.coherentmarketinsights.com/insight/request-sample/6520 Market Trends : One...
PR Newswire
22/05/2024

Pharmaceutical Stability And Storage Services Market Size to Worth USD 4.71 Bn…

Market Dynamics: Market Dynamics: The pharmaceutical stability and storage services market is being primarily driven by the growing demand for outsourcing services in the pharmaceutical industry. Companies are increasingly outsourcing stability testing and storage services to specialized third-party providers to focus on core operations and reduce operational costs. Additionally, stringent regulatory requirements mandating stability testing for drug approval are also fueling the market...
PR Newswire
22/05/2024

Global Non Opioid Pain Treatment Market Size to Worth USD 140.56 Bn By 2031

The growth of the global non-opioid pain treatment market is majorly driven by the increasing preference for non-addictive alternatives to opioid painkillers and growing awareness about the risks and side effects associated with opioid medications. Additionally, favorable government initiatives and reimbursement policies for non-opioid therapies are also contributing to the market growth. However, high costs associated with branded non-opioid medications may hinder the market growth. The…
PR Newswire
22/05/2024

Global Infection Prevention and Control Market is Likely to Increase at a Steady…

Key Takeaways from the Infection Prevention and Control Market Report Key Takeaways from the Infection Prevention and Control Market Report To read more about the latest highlights related to the infection prevention and control market, get a snapshot of the key highlights entailed in theGlobal Infection Prevention and Control Market Report Infection Prevention and Control Overview Infection prevention and control (IPC) is a paramount aspect of healthcare systems worldwide,...
PR Newswire
22/05/2024

Qinecsa Host Industry Discussion on Navigating Post-Marketing Safety…

This online seminar will guide participants through current trends and challenges in the industry, offering valuable insights into best practices and regulatory expectations to navigate the complexities of safety surveillance and ensure compliance with international standards. This online seminar will guide participants through current trends and challenges in the industry, offering valuable insights into best practices and regulatory expectations to navigate the complexities of safety...
PR Newswire
22/05/2024

Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise

COPENHAGEN, Denmark, May 22, 2024– Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 187,020 as a consequence of employees' exercise of warrants. The capital increase was effected without any pre-emption rights for the existing shareholders of the Company or others. A total of 18,702 new shares were subscribed for in cash at DKK 146.60 per share of nominally DKK 10. The total proceeds to Bavarian Nordic A/S from the...
Nasdaq GlobeNewswire
22/05/2024

Philips ePatch and AI analytics platform rolled out to 14 hospitals across Spain…

Philips wearable ePatch and AI analytics platform help detect potentially life-threatening irregular heartbeatsThe solution helps University Hospital Vall d'Hebron achieve reduced average length of stay, relieve emergency room pressure, and reduce costs Amsterdam, the Netherlands, and Madrid, Spain– Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the successful nationwide rollout of its ambulatory cardiac monitoring service in...
Nasdaq GlobeNewswire
22/05/2024

Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE®…

IMCIVREE expected to be funded and available for use in England and Wales within three months through the National Health Service in specialist centres ®(setmelanotide) as an option for treating obesity and the control of hunger (hyperphagia) in genetically confirmed Bardet-Biedl syndrome (BBS) in people 6 years of age and over, if they are between 6 and 17 years of age when treatment starts. Patients may remain on reimbursed setmelanotide as adults whilst they continue to benefit from...
Nasdaq GlobeNewswire
22/05/2024

NeoPhore closes oversubscribed Series B extension round with additional funding…

NeoPhore is focused on building a pipeline of small molecule drugs targeting novel proteins across the MMR pathway to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. Its first-in-class MMR inhibitors induce neoantigen expression and increase immunogenicity in solid tumours that become exquisitely sensitive to immunotherapy. NeoPhore is focused on building a pipeline of small molecule drugs targeting novel proteins across the MMR pathway…
PR Newswire
22/05/2024

SciBase publishes the Annual report for 2023

A printed version of the Annual report will only be distributed to shareholders who actively request a printed copy. A printed version of the Annual report will only be distributed to shareholders who actively request a printed copy. For more information, please contact:Michael Colérus, CFO Tel: +46 70 341 34 72 E-mail:michael.colerus@scibase.com Certified Advisor:Vator Securities Tel: +46 580 065 99 Email:ca@vatorsec.se The information was submitted for publication,...
PR Newswire
22/05/2024

Invitation to presentation of Sectra's year-end report 2023/2024

To participate, follow the instructions on Sectra's website investor.sectra.com/q4report2324. The broadcast will be made available on the same webpage after the conference. To participate, follow the instructions on Sectra's websiteinvestor.sectra.com/q4report2324. The broadcast will be made available on the same webpage after the conference. Participation will take place via Microsoft Teams. Questions can be posed using the chat function or by sending questions in advance via email to...
PR Newswire
22/05/2024

SWIXX BIOPHARMA EXPANDS TO LATIN AMERICA THROUGH A STRATEGIC ACQUISITION AND…

Biopas leadership team remains at the helm of the combined company in Latam. Biopas name will be retained for Latam operations, even as Biopas becomes part of the Swixx BioPharma group. Biopas leadership team remains at the helm of the combined company in Latam. Biopas name will be retained for Latam operations, even as Biopas becomes part of the Swixx BioPharma group. Jean-Michel Lespinasse, CEO of Swixx BioPharma, warmly welcomed the Biopas team into the Swixx BioPharma family: "we...
PR Newswire
22/05/2024

Virtual-Ports Receives CE Certification for Revolutionary Surgical Products

CEO Yuval Yaskil remarked, "Attaining the CE certification under the new MDR requirements not only allows Virtual-Ports to access a long-awaited multi-billion-dollar market, but it is also a testament to the quality and advancement of Virtual-Ports as a company. This milestone underscores our steadfast commitment to empowering surgeons and healthcare systems with cutting-edge solutions that promote safer and more cost-effective clinical outcomes." CEOYuval Yaskilremarked…
PR Newswire
22/05/2024

ZINZINO AB (PUBL): INTERIM REPORT FIRST QUARTER 2024

Revenues in the first quarter of 2024 amounted to SEK 454.5 (393.7) million, corresponding to 15% (18%) growth compared to the corresponding period last year. EBITDA increased to SEK 51.7 (40.8) million and the EBITDA margin to 11.4% (11.3%). During the quarter, a strategic partnership in Europe was entered into with the North American direct sales company ACN, which also invested in 149,468 Zinzino B shares via a directed share issue of SEK 10.4 million. After the end of the period, Zinzino…
PR Newswire
22/05/2024

NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update

PARIS and CAMBRIDGE, Mass., May22, 2024(GLOBE NEWSWIRE) --NANOBIOTIX(Euronext: NANO –– NASDAQ: NBTX – the '' Company ''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational progress and reported financial results for the first quarter of 2024. First Quarter Financial UpdatesCash and Cash Equivalents :Based on the current operating plan and financial...
Nasdaq GlobeNewswire
22/05/2024

OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop…

OSE Immunotherapeuticsand Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases Nantes, France - Ingelheim, Germany - 22 May 2024, 7:30am CET -Today OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and Boehringer Ingelheim announced a major expansion of their partnership.Two new projects to develop first-in-class treatments will be added to the ongoing anti-SIRPα immuno-oncology programs. The first...
Nasdaq GlobeNewswire
22/05/2024

Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a)…

Approximately one in five people worldwide have elevated Lp(a) levels, putting them at increased risk of cardiovascular diseases including myocardial infarction and stroke. 1 The Roche Diagnostics Tina-quant® Lp(a) assay measures lipoprotein (a) in a person's bloodstream, and will be made available on Roche's installed base of over 90,000 serum work area (SWA) systems worldwide. The test has been developed in collaboration with Amgen.Basel, 22 May 2024 - Roche (SIX: RO, ROG;...
Nasdaq GlobeNewswire
22/05/2024
Altri  Comunicati